Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 2360Neoplasms 1709Prostatic Neoplasms 1201Lung Neoplasms 926Colorectal Neoplasms 886Carcinoma, Non-Small-Cell Lung 869Leukemia, Myeloid, Acute 593Pancreatic Neoplasms 578Multiple Myeloma 551Carcinoma, Hepatocellular 518Brain Neoplasms 516Neoplasm Metastasis 462Head and Neck Neoplasms 458Melanoma 417Ovarian Neoplasms 414Glioblastoma 403Precursor Cell Lymphoblastic Leukemia-Lymphoma 400Stomach Neoplasms 377Uterine Cervical Neoplasms 365Squamous Cell Carcinoma of Head and Neck 362Rectal Neoplasms 342Recurrence 337Sarcoma 327Hematologic Neoplasms 324Colonic Neoplasms 323Lymphoma 321Triple Negative Breast Neoplasms 291Carcinoma, Renal Cell 284Glioma 283Urinary Bladder Neoplasms 281

Interventions

tislelizumab 1teprotumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Insulin-Like Growth Factor I, Resistance To × 1 year × Clear all
NCT06866548 2025-12-04

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Shanghai Changzheng Hospital

Phase EARLY_PHASE1 Active not recruiting
7 enrolled
Genitourinary

Insulin-Like Growth Factor I, Resistance To, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡